Simplify Logo
Jazz Pharmaceuticals

Jazz Pharmaceuticals

Biopharmaceuticals focused on neuroscience and oncology

Associate Medical Director - Medical Safety

Full-Time
$212k - $318k/yr
Mid, Senior
MD
Palo Alto, CA, USA+4 more

More locations: London, UK | Cambridge, UK | Philadelphia, PA, USA | Carlsbad, CA, USA

Remote

Some national or international travel may be required.

About the job

Requirements
  • An MD or equivalent degree is required.
  • A minimum of 3 years of Drug Safety/Pharmacovigilance experience or 3 or more years of clinical development experience is required; other relevant experience may be considered.
  • Understanding of the global pharmacovigilance regulatory environment, including international regulations, initiatives, standards, and Good Pharmacovigilance practices in the Americas and European Union, as well as case processing procedures and other pharmacovigilance processes.
  • Working knowledge of safety databases such as ARISg, ARGUS, or other safety database applications, and electronic data capture systems.
  • MedDRA training and working knowledge of MedDRA and WHO Drug coding dictionaries.
  • Ability to manage multiple tasks with deadlines in a fast-paced working environment.
  • Knowledge of the drug development process.
  • A high level of initiative and independence is required.
  • Excellent written and oral communication, resourcefulness, personal organization, and demonstrated cross-functional teamwork are required.
  • Computer literacy with proficiency in external Regulatory Databases, Microsoft Excel, PowerPoint, and Word.
  • Some national or international travel may be required.
Responsibilities
  • Provide Medical Safety and Pharmacovigilance inputs for assigned products, including clinical development programs, investigator-sponsored programs, compassionate use programs, and disease monitoring programs; liaise with Clinical Sciences, Clinical Operations, Medical Affairs, Biometrics, Regulatory Affairs, Contract Research Organizations, Data Monitoring Committees, and other entities to contribute to study execution while ensuring safety strategy and operational excellence.
  • Provide Medical Safety and Pharmacovigilance inputs to the Commercial organization to support global launch activities for assigned products.
  • Participate in preparing and reviewing safety-related sections of clinical, regulatory, and scientific documents, including protocols, informed consent and assent forms, case report forms, statistical plans, clinical study reports and synopses, integrated summaries of safety, New Drug Applications, Biologics License Applications, Marketing Authorization Applications, Common Technical Document submissions, Regulatory Agency responses, Institutional Review Board and Ethics Committee requests, briefing books, manuscripts, and journal articles.
  • Collaborate in creating and maintaining Company Core Safety Information and with the Jazz Labeling Committee to implement it in Reference Safety Information, Investigator Brochures, Company Core Data Sheets, national labels, and associated product labeling.
  • Review medical and scientific literature to identify material relevant to signal detection and aggregate reporting for assigned products.
  • Conduct signal detection activities, including signal identification, evaluation, validation, individual and aggregate data analyses, interpretation of safety signals and trends, and documentation and communication of safety assessments and risks with internal and external stakeholders.
  • Chair the Safety Management Team for products under authority and participate in other executive forums for assigned products.
  • Serve as signatory and oversee preparation and review of pre- and post-marketing aggregate safety reports, including Periodic Safety Update Reports, Periodic Benefit Risk Evaluation Reports, Periodic Adverse Drug Experience Reports, Development Safety Update Reports, Investigational New Drug annual reports, and six-month Suspected Unexpected Serious Adverse Reaction line-listing reports; ensure consistent communication of safety profiles and topics across regulatory safety documents.
  • Contribute to preparing Risk Management Plans, including identifying risks and appropriate risk-minimization and effectiveness measures in accordance with regulatory requirements.
  • Provide guidance on adverse-event MedDRA and drug WHO Drug coding for clinical and post-marketing safety data.
  • Ensure compliance with applicable global pharmacovigilance regulations and guidelines, Standard Operating Procedures, and quality standards; participate in inspection readiness activities, internal audits, and external inspections.
  • Represent Pharmacovigilance in cross-functional forums and committees involving products under responsibility.
  • Contribute to key performance indicators to ensure Pharmacovigilance excellence.
  • Maintain knowledge of Jazz Pharmaceuticals indications for assigned investigational and marketed products.
  • Keep abreast of new pharmacovigilance and safety regulations and guidance from regulatory authorities.
Desired Qualifications
  • Medical licensure in at least one state is preferred.
  • Clinical research and/or fellowship training in internal medicine or neuroscience, hematology/oncology, or another relevant specialty is a plus.
  • Working experience with the pharmacovigilance audit process and active participation in Regulatory Authority Inspections is preferred.

About the company

Jazz Pharmaceuticals develops and markets therapies in neuroscience and oncology. Its products include Xyrem and the lower-sodium option Xywav for narcolepsy, Epidiolex for seizures in severe epilepsy, and oncology medicines Zepzelca for small cell lung cancer and Vyxeos for AML, with Epidiolex being cannabidiol-based. The company grows its portfolio through a mix of in-house R&D and strategic acquisitions that broaden its specialty-drug lineup and global reach. Its goal is to expand approved treatments and the pipeline to help patients with limited options by building a diversified, specialty-focused portfolio.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dublin, Ireland

Founded

2003

Get referred to Jazz Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Ziihera's August 2026 FDA win expands Jazz into a $3 billion-to-$5 billion opportunity.
  • Q2 2026 revenue reached $1.21 billion, and guidance rose to $4.60 billion-$4.75 billion.
  • Actio Biosciences acquisition closed September 15, 2026, adding KCNT1+ epilepsy upside.

What critics are saying

  • Tris Pharma filed generic Xywav and Xyrem applications in January 2026, threatening 2027 pricing.
  • Long-term debt was $4.4 billion at June 30, 2026, limiting flexibility for pipeline deals.
  • Zepzelca's failed second-line SCLC trial narrows growth if first-line maintenance adoption slows.

What makes Jazz Pharmaceuticals unique

  • Xywav's low-sodium profile keeps narcolepsy and idiopathic hypersomnia patients on therapy.
  • Ziihera became Jazz's first FDA-approved HER2-targeted backbone for first-line GEA on August 25, 2026.
  • Jazz combines rare sleep, epilepsy, and oncology commercialization across one scaled specialty platform.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

0%
Yahoo Finance
Sep 11th, 2026
Jazz Pharmaceuticals stock climbs 29.7% but analysts warn of declining margins and weak returns

Jazz Pharmaceuticals' stock has risen 29.7% over the past six months, outpacing the S&P 500 by 17 percentage points to reach $240.49 per share. However, analysts point to concerning trends in the company's fundamentals. The company's adjusted operating margin has declined by 2.6 percentage points over five years, despite revenue growth that should have improved economies of scale. Its trailing 12-month adjusted operating margin stood at 41.7%. Additionally, Jazz Pharmaceuticals' five-year average return on invested capital was just 2.7%, below the typical cost of capital for healthcare companies. This suggests mediocre efficiency in deploying capital for growth. The stock currently trades at 9.6× forward price-to-earnings ratio. Analysts consider this valuation reasonable but believe the company's weakening fundamentals present downside risk.

StockTitan
Aug 27th, 2026
Jazz Pharmaceuticals prices upsized $1.1B exchangeable notes offering with $225M share repurchase

Jazz Pharmaceuticals has priced an upsized $1.1 billion private offering of 1.875% exchangeable senior notes due 2032, up from the previously announced $1.0 billion. The offering, conducted through its wholly-owned subsidiary Jazz Investments I Limited, is expected to close on 31 August 2026. The notes will mature on 15 September 2032 and are exchangeable at an initial rate of 2.8150 ordinary shares per $1,000 principal amount, equivalent to an exchange price of approximately $355.24 per share. This represents a 42.5% premium above the last reported sale price on 26 August 2026. The company will use net proceeds of approximately $1,079 million for general corporate purposes. Concurrently, Jazz Pharmaceuticals agreed to repurchase approximately $225 million of its ordinary shares from note purchasers at $249.29 per share, using existing cash on hand.

Yahoo Finance
Aug 26th, 2026
Jazz Pharmaceuticals launches Ziihera for HER2-positive cancer with $3B–$5B peak sales outlook

Jazz Pharmaceuticals has launched Ziihera in the US following FDA approval for first-line treatment of HER2-positive, unresectable or metastatic gastroesophageal adenocarcinoma. The drug can be used with tislelizumab and chemotherapy, or with chemotherapy alone for certain patients. In the Phase III HERIZON-GEA-01 trial, Ziihera-based regimens reduced the risk of disease progression or death by 35%. The triplet regimen extended median overall survival to 26.4 months, a 28% reduction in death risk versus trastuzumab. Jazz estimates the US addressable market at 3,000–4,000 patients annually and raised Ziihera's peak sales outlook to $3 billion–$5 billion. The company plans to leverage existing commercial infrastructure whilst pursuing additional cancer indications and international regulatory filings.

Yahoo Finance
Aug 11th, 2026
Jazz Pharmaceuticals Q2 revenue beats estimates at $1.21B, ups guidance to $4.68B

Jazz Pharmaceuticals reported a strong second quarter with revenue of $1.21 billion, beating analyst estimates of $1.12 billion and representing 15.5% year-on-year growth. The company raised its full-year revenue guidance to $4.68 billion from $4.38 billion. CEO Renée Galá attributed the performance to strong demand for flagship products like Xywav and Epidiolex, alongside accelerating uptake of new oncology therapies. Operating margin improved to 20.5%, up from negative 65.6% in the prior year quarter. However, adjusted earnings per share of $5.71 missed analyst expectations of $6.18. During the earnings call, analysts focused on Epidiolex's growth drivers, Xywav's sustainability amid potential generic competition, and zanidatamab's upcoming approval prospects.

Yahoo Finance
Aug 11th, 2026
Jazz Pharma raises 2026 guidance on record Q2 revenue of $1.2B, up 16%

Jazz Pharmaceuticals reported record second quarter revenue of $1.2 billion, representing 16% year-over-year growth. The company raised its full-year revenue guidance based on strong first-half performance. Chief executive officer Renée Galá attributed the results to execution across the company's diversified portfolio and sustained demand for its commercial products. The company is preparing to launch zanidatamab, with a PDUFA date of 25 August for treatment of first-line HER2-positive metastatic gastroesophageal adenocarcinoma. The earnings call included updates from senior leadership, including chief commercial officer Samantha Pearce, global head of research and development Robert Iannone, and chief financial officer Philip Johnson. Jazz Pharmaceuticals highlighted progress on its long-term value creation priorities whilst maintaining focus on current commercial operations.